{
    "nct_id": "NCT05229601",
    "official_title": "A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients With Advanced Solid Tumors",
    "inclusion_criteria": "* Previously received the following lines of systemic therapy for the advanced/metastatic disease:\n\n  * Soft tissue sarcoma: at least 1 line of therapy\n  * Renal cell carcinoma: at least 2 lines of therapy;\n  * Uterine carcinosarcoma: at least 1 line of therapy;\n  * Hepatocellular carcinoma: at least 1 line of therapy\n  * Head and neck squamous cell carcinoma: at least 2 lines of therapy\n  * Melanoma:\n\n    * BRAF V600E mutant: must have received at least 2 lines of therapy\n    * BRAF V600E wild type: must have received at least 1 line of therapy\n* Suitable site to biopsy at pre-treatment and on-treatment\n* Measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-RECIST (iRECIST)\n* Eastern Cooperative Oncology Group performance status of 0 or 1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Systemic anti-cancer therapy within 2 weeks prior to start of study drug.\n* For soft tissue sarcoma only: prior immune therapy or immune agonist antibodies\n* For uterine carcinosarcoma patients only: prior immune therapy\n* Therapeutic radiation therapy within the past 2 weeks\n* Prior exposure to agents targeting the OX40 receptor;\n* Active autoimmune disease requiring systemic treatment in the previous 2 years;\n* Systemic steroid therapy (>10 mg/day of prednisone or equivalent) or any immune suppressive therapy.\n* Persisting toxicity of >Grade 1 relating to prior anti cancer therapy with the following exceptions:\n\n  * All grades of alopecia are acceptable;\n  * Endocrine dysfunction on replacement therapy is acceptable.\n* Severe or unstable medical condition, including uncontrolled diabetes, coagulopathy, or unstable psychiatric condition;\n* Major surgery within 2 weeks of the first dose of study drug;\n* History or presence of drug or non-drug induced interstitial lung disease or pneumonitis â‰¥Grade 2;\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to monoclonal antibodies or any excipient of HFB301001;\n* Known active malignancy, with the exception of the specific cancer under investigation in this trial, that required treatment within the previous 2 years.",
    "miscellaneous_criteria": ""
}